MedPath

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Phase 3
Recruiting
Conditions
Ischemic Stroke, Acute
Interventions
Registration Number
NCT06157502
Lead Sponsor
Beijing Tiantan Hospital
Brief Summary

Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.

Detailed Description

Intravenous thrombolysis with rt-PA within the time window is the most effective drug for acute ischemic stroke, but there are still more than 50% patients with functional disability. Neuroprotective agents can reduce brain cell death after cerebral ischemia by blocking all links of ischemic cascade. Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy.

This study is a multicenter, randomized, double-blind, placebo-parallel controlled trial. A total of 1380 patients from 50 centers in China who could be treated within 6 hours of onset and have received or plan to undergo intravenous thrombolytic therapy will be enrolled and randomly assigned, in a 1:1 ratio, to receive Shuxuening injection (20 ml Shuxuening injection + 250 ml 0.9% sodium chloride injection), or to receive Shuxuening injection placebo (20 ml plus 250 ml 0.9% sodium chloride injection); both groups are treated for 10-14 days. The primary efficacy outcome is mRS Score 0 to 1 at 90 days, and the primary safety outcome is adverse events within 90 days.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1380
Inclusion Criteria
  • Age 18 or older;
  • Diagnosed with acute ischemic stroke;
  • Within 6 hours of onset;
  • Having received or plan to undergo intravenous thrombolytic therapy;
  • NIHISS score of 4 to 25 points at enrollment;
  • Signed informed consent.
Exclusion Criteria
  • mRS score greater than 1 point before the onset;
  • Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset;
  • Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT/MRI;
  • History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
  • Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to the ALT or AST levels above 3 times the upper limit of normal; severe renal insufficiency refers to the creatinine levels above 2 times the upper limit of normal);
  • Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgo biloba extract);
  • Women who are pregnant or breastfeeding, and women of childbearing age who have a negative pregnancy test but refuse to take effective contraceptive measures;
  • Participation in another clinical trial with an experimental product during the last 30 days;
  • Other participants deemed unsuitable for participation in this study by the investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo + Intravenous Thrombolysis
Shuxuening injectionShuxuening InjectionShuxuening Injection + Intravenous Thrombolysis
Primary Outcome Measures
NameTimeMethod
The proportion of mRS score 0 to 1 at 90 days after randomizationAt 90 days after randomization

The Modified Rankin Scale (mRS) score ranges from 0 to 6, with higher scores indicating worse functional outcome.

Secondary Outcome Measures
NameTimeMethod
The proportion of mRS score 0 to 2 at 90 days after randomizationAt 90 days after randomization

The Modified Rankin Scale (mRS) score ranges from 0 to 6, with higher scores indicating worse functional outcome.

The distribution of mRS scores at 90 days after randomizationAt 90 days after randomization

The Modified Rankin Scale (mRS) score ranges from 0 to 6, with higher scores indicating worse functional outcome.

NIHSS score improvement ≥4 points from baseline at 14 days after randomization or on dischargeAt 14 days after randomization or on discharge

The National Institutes of Health Stroke Scale (NIHSS) score ranges from 0 to 42, with higher scores indicating more severe neurological deficit.

EQ-5D score at 90 days after randomizationAt 90 days after randomization

The European Quality of Life 5-Dimension 3-Level (EQ-5D-3L) includes five dimensions. The sum score on each of the five dimensions ranges from 5 (all domains have level 1) to 15 (all domains have level 3), with higher scores indicating worse health-related quality of life.

Serious adverse events within 90 days after randomizationWithin 90 days after randomization
The proportion of Barthel index score ≥95 points at 90 days after randomizationAt 90 days after randomization

The Barthel index score ranges from 0 to 100, with higher scores indicating greater independence.

All-cause death within 90 days after randomizationWithin 90 days after randomization
Adverse events within 90 days after randomizationWithin 90 days after randomization
Symptomatic intracranial hemorrhage (ECASS-III) within 90 days after randomizationWithin 90 days after randomization
Symptomatic intracranial hemorrhage (SITS-MOST PH2) within 90 days after randomizationWithin 90 days after randomization

Trial Locations

Locations (82)

Wuchuan Gelao and Miao Autonomous County Hospital of Traditional Chinese Medicine

🇨🇳

Zunyi, Guizhou, China

Wuchang Hospital of Traditional Chinese Medicine

🇨🇳

Harbin, Heilongjiang, China

Pingdingshan First People's Hospital

🇨🇳

Pingdingshan, Henan, China

Qinhuangdao Second Hospital

🇨🇳

Qinhuangdao, Henan, China

Wuhan Fifth Hospital

🇨🇳

Wuhan, Hubei, China

Zhalantun People's Hospital

🇨🇳

Hulunbuir, Inner Mongolia, China

Xinhua Hospital Affiliated to Dalian University

🇨🇳

Dalian, Liaoning, China

Yuci District People's Hospital

🇨🇳

Jinzhong, Shanxi, China

Fangshan District First Hospital

🇨🇳

Beijing, Beijing, China

Chongqing Nanchuan District People's Hospital

🇨🇳

Chongqing, Chongqing, China

Chongqing Sanbo Chang'an Hospital

🇨🇳

Chongqing, Chongqing, China

Chongqing Qianjiang Central Hospital

🇨🇳

Qianjiang, Chongqing, China

The First Affiliated Hospital of Guangdong Pharmaceutical University

🇨🇳

Guangzhou, Guangdong, China

Heyuan People's Hospital

🇨🇳

Heyuan, Guangdong, China

Huazhou People's Hospital

🇨🇳

Maoming, Guangdong, China

Meizhou Hospital of Traditional Chinese Medicine

🇨🇳

Meizhou, Guangdong, China

Yunfu People's Hospital

🇨🇳

Yunfu, Guangdong, China

Zhongshan People's Hospital

🇨🇳

Zhongshan, Guangdong, China

Wuchuan People's Hospital

🇨🇳

Zhanjiang, Guangdong, China

The Fifth Affiliated Hospital of Sun Yat-sen University

🇨🇳

Zhuhai, Guangdong, China

Wuming Hospital Affiliated to Guangxi Medical College

🇨🇳

Nanning, Guangxi, China

Zunyi First People's Hospital

🇨🇳

Zunyi, Guizhou, China

Baoding Xushui District People's Hospital

🇨🇳

Baoding, Hebei, China

The Second Affiliated Hospital of Harbin Medical University

🇨🇳

Harbin, Heilongjiang, China

Puyang Anyang District Hospital

🇨🇳

Anyang, Henan, China

Jiaozuo Coal Industry (Group) Co. Ltd. Central Hospital

🇨🇳

Jiaozuo, Henan, China

Jiyuan Hospital of Traditional Chinese Medicine

🇨🇳

Jiyuan, Henan, China

Mengzhou Hospital of Traditional Chinese Medicine

🇨🇳

Jiaozuo, Henan, China

Wenxian People's Hospital

🇨🇳

Jiaozuo, Henan, China

Kaifeng Central Hospital

🇨🇳

Kaifeng, Henan, China

Lankao First Hospital

🇨🇳

Kaifeng, Henan, China

Luohe Third People's Hospital

🇨🇳

Luohe, Henan, China

Luoyang Yanshi People's Hospital

🇨🇳

Luoyang, Henan, China

Pingdingshan Second People's Hospital

🇨🇳

Pingdingshan, Henan, China

Nanle Zhongxing Hospital

🇨🇳

Puyang, Henan, China

Lingbao First People's Hospital

🇨🇳

Sanmenxia, Henan, China

Shangqiu First People's Hospital

🇨🇳

Shangqiu, Henan, China

Shangqiu Third Prople's Hospital

🇨🇳

Shangqiu, Henan, China

Shangqiu Fourth People's Hospital

🇨🇳

Shangqiu, Henan, China

Suixian People's Hospital

🇨🇳

Shangqiu, Henan, China

Suixian Hospital of Traditional Chinese Medicine

🇨🇳

Shangqiu, Henan, China

Xiayi People's Hospital

🇨🇳

Shangqiu, Henan, China

Yongcheng Central Hospital

🇨🇳

Shangqiu, Henan, China

Yongcheng People's Hospital

🇨🇳

Shangqiu, Henan, China

Huixian People's Hospital

🇨🇳

Xinxiang, Henan, China

The First Affiliated Hospital of Xinxiang Medical University

🇨🇳

Xinxiang, Henan, China

Jingmen Hospital of Traditional Chinese Medicine

🇨🇳

Jingmen, Hubei, China

Jingzhou First People's Hospital

🇨🇳

Jingzhou, Hubei, China

Wuhan Central Hospital

🇨🇳

Wuhan, Hubei, China

Wuhan Hankou Hospital

🇨🇳

Wuhan, Hubei, China

Wuhan Huangpi District People's Hospital

🇨🇳

Wuhan, Hubei, China

Shaodong People's Hospital

🇨🇳

Shaoyang, Hunan, China

Zhongnan Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

Liuyang Jili Hospital

🇨🇳

Changsha, Hunan, China

Chenzhou First People's Hospital

🇨🇳

Chenzhou, Hunan, China

The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

🇨🇳

Baotou, Inner Mongolia, China

Inner Mongolia Hangtian Hospital

🇨🇳

Hohhot, Inner Mongolia, China

Tuquan People's Hospital

🇨🇳

Hinggan, Inner Mongolia, China

Zalantun Zhongmeng Hospital

🇨🇳

Hulunbuir, Inner Mongolia, China

Huai'an Second People's Hospital

🇨🇳

Huai'an, Jiangsu, China

Haicheng Hospital of Traditional Chinese Medicine

🇨🇳

Anshan, Liaoning, China

Benxi Central Hospital

🇨🇳

Benxi, Liaoning, China

Dandong Central Hospital

🇨🇳

Dandong, Liaoning, China

The First Affiliated Hospital of Jinzhou Medical University

🇨🇳

Jinzhou, Liaoning, China

Shenyang First People's Hospital

🇨🇳

Shenyang, Liaoning, China

Yan'an University Affiliated Hospital

🇨🇳

Yan'an, Shaanxi, China

The First Affiliated Hospital of Xi'an Jiao Tong University

🇨🇳

Xi'an, Shaanxi, China

Ningjin People's Hospital

🇨🇳

Dezhou, Shandong, China

Shandong Provincial Public Health Clinical Center

🇨🇳

Jinan, Shandong, China

Yuncheng People's Hospital

🇨🇳

Heze, Shandong, China

Guanxian People's Hospital

🇨🇳

Liaocheng, Shandong, China

Weihai Wendeng District People' Hospital

🇨🇳

Weihai, Shangdong, China

Liaocheng Third People's Hospital

🇨🇳

Liaocheng, Shangdong, China

Linshu People's Hospital

🇨🇳

Linyi, Shandong, China

Yantai Yeda Hospital

🇨🇳

Yantai, Shangdong, China

Zibo Municipal Hospital

🇨🇳

Zibo, Shangdong, China

Jincheng People's Hospital

🇨🇳

Jincheng, Shanxi, China

Linfen Central Hospital

🇨🇳

Linfen, Shanxi, China

Linfen People's Hospital

🇨🇳

Linfen, Shanxi, China

Tianjin Xiqing Hospital

🇨🇳

Tianjin, Tianjin, China

Yunnan Third People's Hospital

🇨🇳

Kunming, Yunnan, China

The First Affiliated Hospital of Shihezi University Medical College

🇨🇳

Shihezi, Xinjiang, China

© Copyright 2025. All Rights Reserved by MedPath